FI112168B - Menetelmä anti-D-immunoglobuliini G-konsentraatin valmistamiseksi - Google Patents
Menetelmä anti-D-immunoglobuliini G-konsentraatin valmistamiseksi Download PDFInfo
- Publication number
- FI112168B FI112168B FI946103A FI946103A FI112168B FI 112168 B FI112168 B FI 112168B FI 946103 A FI946103 A FI 946103A FI 946103 A FI946103 A FI 946103A FI 112168 B FI112168 B FI 112168B
- Authority
- FI
- Finland
- Prior art keywords
- igg
- plasma
- adsorbent
- rhesus
- fraction
- Prior art date
Links
- 229940027941 immunoglobulin g Drugs 0.000 title claims abstract description 5
- 239000012141 concentrate Substances 0.000 title abstract description 7
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000003463 adsorbent Substances 0.000 claims abstract description 16
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 10
- 125000000524 functional group Chemical group 0.000 claims abstract description 7
- 238000005342 ion exchange Methods 0.000 claims abstract description 7
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 39
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000003599 detergent Substances 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 4
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 4
- -1 diethylaminoethyl groups Chemical group 0.000 claims description 4
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000011140 membrane chromatography Methods 0.000 claims description 2
- 238000005191 phase separation Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims 3
- 238000011534 incubation Methods 0.000 claims 2
- 238000005119 centrifugation Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 15
- 239000012064 sodium phosphate buffer Substances 0.000 description 15
- 108060003951 Immunoglobulin Proteins 0.000 description 14
- 102000018358 immunoglobulin Human genes 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000005277 cation exchange chromatography Methods 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101000894412 Mycolicibacterium paratuberculosis (strain ATCC BAA-968 / K-10) Bacterioferritin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010063676 Rhesus incompatibility Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940081001 glycine 20.6 mg/ml Drugs 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229940080930 mannitol 50 mg/ml Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93810912A EP0659767B2 (de) | 1993-12-27 | 1993-12-27 | Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält |
| EP93810912 | 1993-12-27 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI946103A0 FI946103A0 (fi) | 1994-12-27 |
| FI946103L FI946103L (fi) | 1995-06-28 |
| FI112168B true FI112168B (fi) | 2003-11-14 |
Family
ID=8215103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI946103A FI112168B (fi) | 1993-12-27 | 1994-12-27 | Menetelmä anti-D-immunoglobuliini G-konsentraatin valmistamiseksi |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5593675A (cs) |
| EP (1) | EP0659767B2 (cs) |
| JP (1) | JP2926463B2 (cs) |
| KR (1) | KR100368563B1 (cs) |
| AT (1) | ATE175979T1 (cs) |
| AU (1) | AU682243B2 (cs) |
| CA (1) | CA2138921C (cs) |
| CZ (1) | CZ286271B6 (cs) |
| DE (1) | DE59309332D1 (cs) |
| DK (1) | DK0659767T4 (cs) |
| ES (1) | ES2129076T5 (cs) |
| FI (1) | FI112168B (cs) |
| GR (1) | GR3029817T3 (cs) |
| HU (1) | HU216864B (cs) |
| NO (1) | NO315331B1 (cs) |
| NZ (1) | NZ278057A (cs) |
| PL (1) | PL180358B1 (cs) |
| SI (1) | SI9420008B (cs) |
| TW (1) | TW311884B (cs) |
| WO (1) | WO1995018155A1 (cs) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999057134A1 (en) * | 1998-05-06 | 1999-11-11 | Genentech, Inc. | Protein purification by ion exchange chromatography |
| JP4685238B2 (ja) * | 1998-06-09 | 2011-05-18 | ツエー・エス・エル・ベーリング・アクチエンゲゼルシヤフト | 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法 |
| DE19923027C2 (de) * | 1999-05-19 | 2002-09-19 | Aventis Behring Gmbh | Verfahren zur Inaktivierung von Viren |
| US6475749B1 (en) * | 1999-08-11 | 2002-11-05 | The Regents Of The University Of California | Rh hybrid antibody |
| SE0001128D0 (sv) * | 2000-03-30 | 2000-03-30 | Amersham Pharm Biotech Ab | A method of producing IgG |
| ES2184594B1 (es) * | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| CA2458750C (en) | 2004-02-23 | 2012-02-07 | Bayer Inc. | Isoolefin-diolefin production process and apparatus therefor |
| US20060263357A1 (en) * | 2005-05-05 | 2006-11-23 | Tedder Thomas F | Anti-CD19 antibody therapy for autoimmune disease |
| TWI391399B (zh) | 2005-05-25 | 2013-04-01 | Hoffmann La Roche | 測定溶離多肽之鹽濃度之方法 |
| EA017733B1 (ru) * | 2006-08-28 | 2013-02-28 | Арес Трейдинг С.А. | СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ |
| WO2008025748A1 (en) * | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-containing proteins |
| IT1397061B1 (it) * | 2009-12-28 | 2012-12-28 | Kedrion Spa | Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale. |
| JP6078344B2 (ja) | 2010-02-04 | 2017-02-08 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | 免疫グロブリン製剤 |
| EP2361636A1 (en) | 2010-02-26 | 2011-08-31 | CSL Behring AG | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
| RU2467783C2 (ru) * | 2010-07-30 | 2012-11-27 | Закрытое акционерное общество "БиоХимМак СТ" | Способ хроматографического выделения иммуноглобулина |
| EA027353B1 (ru) * | 2010-09-17 | 2017-07-31 | Баксалта Инкорпорейтид | СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО |
| CN103874708B (zh) | 2011-08-26 | 2018-07-10 | 百深有限责任公司 | 用于降低血浆来源免疫球蛋白组合物的血栓栓塞可能性的方法 |
| AU2013203043B2 (en) * | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| US10287315B2 (en) * | 2014-03-11 | 2019-05-14 | Green Cross Holdings Corporation | Method for purifying immunoglobulin |
| KR101917197B1 (ko) * | 2014-03-11 | 2018-11-09 | 주식회사 녹십자홀딩스 | 면역글로불린의 정제방법 |
| CN106999588A (zh) | 2014-12-03 | 2017-08-01 | 瑞士杰特贝林生物制品有限公司 | 具有增加的稳定性的包含免疫球蛋白的药物产品 |
| MA52945A (fr) * | 2018-06-22 | 2021-04-28 | Genmab As | Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents |
| EP4349859A1 (en) * | 2023-01-27 | 2024-04-10 | CSL Behring AG | Method to purify anti-d immunoglobulin g from plasma |
| WO2024156861A1 (en) * | 2023-01-27 | 2024-08-02 | Csl Behring Ag | Method for reducing protease activity in a solution comprising anti-d immunoglobulin g |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3869436A (en) * | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
| ATE19735T1 (de) * | 1982-02-08 | 1986-05-15 | Schweiz Serum & Impfinst | Intravenoes verabreichbares humanes immunglobulin und verfahren zu dessen herstellung. |
| US4434093A (en) * | 1982-07-26 | 1984-02-28 | Ortho Diagnostic Systems Inc. | Methods for preparation of HBs Ag free gamma globulins |
| DE3640513A1 (de) * | 1986-11-27 | 1988-06-09 | Biotest Pharma Gmbh | Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates |
| US5118796A (en) * | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
| US5138034A (en) * | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
| US5177194A (en) * | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
-
1993
- 1993-12-27 EP EP93810912A patent/EP0659767B2/de not_active Expired - Lifetime
- 1993-12-27 ES ES93810912T patent/ES2129076T5/es not_active Expired - Lifetime
- 1993-12-27 AT AT93810912T patent/ATE175979T1/de active
- 1993-12-27 DE DE59309332T patent/DE59309332D1/de not_active Expired - Lifetime
- 1993-12-27 DK DK93810912T patent/DK0659767T4/da active
-
1994
- 1994-12-21 US US08/360,334 patent/US5593675A/en not_active Expired - Lifetime
- 1994-12-22 CA CA002138921A patent/CA2138921C/en not_active Expired - Fee Related
- 1994-12-22 SI SI9420008A patent/SI9420008B/sl unknown
- 1994-12-22 CZ CZ19952492A patent/CZ286271B6/cs not_active IP Right Cessation
- 1994-12-22 PL PL94310435A patent/PL180358B1/pl not_active IP Right Cessation
- 1994-12-22 KR KR1019950703644A patent/KR100368563B1/ko not_active Expired - Fee Related
- 1994-12-22 HU HU9502514A patent/HU216864B/hu not_active IP Right Cessation
- 1994-12-22 AU AU14143/95A patent/AU682243B2/en not_active Ceased
- 1994-12-22 NZ NZ278057A patent/NZ278057A/en not_active IP Right Cessation
- 1994-12-22 WO PCT/EP1994/004267 patent/WO1995018155A1/en not_active Ceased
- 1994-12-23 NO NO19945032A patent/NO315331B1/no not_active IP Right Cessation
- 1994-12-27 JP JP6337017A patent/JP2926463B2/ja not_active Expired - Fee Related
- 1994-12-27 FI FI946103A patent/FI112168B/fi not_active IP Right Cessation
-
1995
- 1995-01-10 TW TW084100147A patent/TW311884B/zh not_active IP Right Cessation
-
1999
- 1999-03-30 GR GR990400907T patent/GR3029817T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI112168B (fi) | Menetelmä anti-D-immunoglobuliini G-konsentraatin valmistamiseksi | |
| US5886154A (en) | Chromatographic method for high yield purification and viral inactivation of antibodies | |
| AU731950B2 (en) | Concentrated antibody preparation | |
| US6955917B2 (en) | Chromatographic method for high yield purification and viral inactivation of antibodies | |
| KR100236762B1 (ko) | 사람 혈장의 분별 동안에 생성된 분별물로부터 면역글로불린을 회수하는 방법 | |
| JPH0365327B2 (cs) | ||
| Hässig | Intravenous immunoglobulins: pharmacological aspects and therapeutic use | |
| EP0973549A2 (en) | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties | |
| HK1009277A1 (en) | Process to prepare an anti-d immunoglobulin g concentrate and pharmaceutical compositions comprising it | |
| HK1009277B (en) | Process to prepare an anti-d immunoglobulin g concentrate and pharmaceutical compositions comprising it | |
| Yap | Humoral Functions of Immunoglobulin: Relationship to Purification Technology of Intravenous Immunoglobulin | |
| MXPA98009645A (en) | Concentrated preparation of anticuer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: ZLB BEHRING AG Free format text: ZLB BEHRING AG |
|
| PC | Transfer of assignment of patent |
Owner name: CSL BEHRING AG Free format text: CSL BEHRING AG |
|
| MM | Patent lapsed |